Wednesday, July 26, 2017

Enter Title


 Opsumit - New treatment for PAH now available on the PBS

Email not displaying correctly?
View it in your browser.
View at

Opsumit® (macitentan) – New treatment for pulmonary arterial hypertension (PAH) now available on the PBS


1 September 2014: Actelion Pharmaceuticals Australia Pty Ltd today announced the availability of Opsumit®  (macitentan) 10mg, a new endothelin receptor antagonist (ERA) for the treatment of pulmonary arterial hypertension (PAH), on the Pharmaceutical Benefits Scheme (PBS).
Opsumit® is PBS listed for idiopathic PAH, anorexigen-induced PAH, hereditable PAH, drug-induced PAH, PAH secondary to connective tissue disease including scleroderma, or PAH associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).
In Australia, Opsumit® is Therapeutic Goods Administration (TGA) approved for the treatment of idiopathic and heritable PAH as well as PAH associated with connective tissue disease and PAH associated with congenital heart disease with repaired shunts, in patients with WHO Functional class II-IV symptoms. 

For more information please refer to the Actelion Website.

*|FACEBOOK:LIKE|**|MC:TOPSHARE|*  Forward to Friend 
Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.

Our mailing address is:
unsubscribe from this list   update subscription preferences 
Copyright 2011 by PHSANZ